156 related articles for article (PubMed ID: 25322440)
21. Randomized two-stage Phase II clinical trial designs based on Barnard's exact test.
Shan G; Ma C; Hutson AD; Wilding GE
J Biopharm Stat; 2013; 23(5):1081-90. PubMed ID: 23957517
[TBL] [Abstract][Full Text] [Related]
22. Interim analysis of binary outcome data in clinical trials: a comparison of five estimators.
Lu QS; Chow SC; Tse SK
J Biopharm Stat; 2019; 29(2):400-410. PubMed ID: 30599798
[TBL] [Abstract][Full Text] [Related]
23. Survival trial design and monitoring using historical controls.
Wu J; Xiong X
Pharm Stat; 2016 Sep; 15(5):405-11. PubMed ID: 27307025
[TBL] [Abstract][Full Text] [Related]
24. SUN vs BEVthornIFN in first-line mRCC therapy: no evidence for a statistically significant difference in progression-free survival.
Nuijten M; Mickisch G
Br J Cancer; 2010 Jan; 102(1):232-3; author reply 234-5. PubMed ID: 20051962
[No Abstract] [Full Text] [Related]
25. Group sequential testing for cluster randomized trials with time-to-event endpoint.
Li J; Jung SH
Biometrics; 2022 Dec; 78(4):1353-1364. PubMed ID: 34076257
[TBL] [Abstract][Full Text] [Related]
26. Optimal Futility Interim Design: A Predictive Probability of Success Approach with Time-to-Event Endpoint.
Tang Z
J Biopharm Stat; 2015; 25(6):1312-9. PubMed ID: 25379701
[TBL] [Abstract][Full Text] [Related]
27. A logrank test-based method for sizing clinical trials with two co-primary time-to-event endpoints.
Sugimoto T; Sozu T; Hamasaki T; Evans SR
Biostatistics; 2013 Jul; 14(3):409-21. PubMed ID: 23307913
[TBL] [Abstract][Full Text] [Related]
28. Optimal response-adaptive randomized designs for multi-armed survival trials.
Sverdlov O; Tymofyeyev Y; Wong WK
Stat Med; 2011 Oct; 30(24):2890-910. PubMed ID: 21823146
[TBL] [Abstract][Full Text] [Related]
29. A behavioural Bayes approach to the determination of sample size for clinical trials considering efficacy and safety: imbalanced sample size in treatment groups.
Kikuchi T; Gittins J
Stat Methods Med Res; 2011 Aug; 20(4):389-400. PubMed ID: 20223784
[TBL] [Abstract][Full Text] [Related]
30. Clinical trial designs based on sequential conditional probability ratio tests and reverse stochastic curtailing.
Tan M; Xiong X; Kutner MH
Biometrics; 1998 Jun; 54(2):682-95. PubMed ID: 9629648
[TBL] [Abstract][Full Text] [Related]
31. Design of sequentially randomized trials for testing adaptive treatment strategies.
Ogbagaber SB; Karp J; Wahed AS
Stat Med; 2016 Mar; 35(6):840-58. PubMed ID: 26412033
[TBL] [Abstract][Full Text] [Related]
32. Simultaneous use of weighted logrank and standardized Kaplan-Meier statistics.
Yang P; Fleming TR
J Biopharm Stat; 2006; 16(2):241-52. PubMed ID: 16584070
[TBL] [Abstract][Full Text] [Related]
33. Using joint utilities of the times to response and toxicity to adaptively optimize schedule-dose regimes.
Thall PF; Nguyen HQ; Braun TM; Qazilbash MH
Biometrics; 2013 Sep; 69(3):673-82. PubMed ID: 23957592
[TBL] [Abstract][Full Text] [Related]
34. Determination of hazard ratio for progression-free survival considering the tumor assessment schedule in sample size calculation.
Tanase T
Pharm Stat; 2020 Mar; 19(2):126-136. PubMed ID: 32067336
[TBL] [Abstract][Full Text] [Related]
35. Modified Goldilocks Design with strict type I error control in confirmatory clinical trials.
Zhan T; Zhang H; Hartford A; Mukhopadhyay S
J Biopharm Stat; 2020 Sep; 30(5):821-833. PubMed ID: 32297825
[TBL] [Abstract][Full Text] [Related]
36. A note on P-values under group sequential testing and nonproportional hazards.
Gillen DL; Emerson SS
Biometrics; 2005 Jun; 61(2):546-51. PubMed ID: 16011703
[TBL] [Abstract][Full Text] [Related]
37. Sample size calculations for evaluating treatment policies in multi-stage designs.
Dawson R; Lavori PW
Clin Trials; 2010 Dec; 7(6):643-52. PubMed ID: 20630903
[TBL] [Abstract][Full Text] [Related]
38. On group sequential designs comparing two binomial proportions.
Kepner JL
J Biopharm Stat; 2010 Jan; 20(1):145-59. PubMed ID: 20077254
[TBL] [Abstract][Full Text] [Related]
39. Improving efficiency in clinical trials using auxiliary information: Application of a multi-state cure model.
Conlon AS; Taylor JM; Sargent DJ
Biometrics; 2015 Jun; 71(2):460-8. PubMed ID: 25585942
[TBL] [Abstract][Full Text] [Related]
40. An urn model for odds-ratio-based response-adaptive phase III clinical trials for two or more treatments.
Basak GK; Biswas A; Volkov S
J Biopharm Stat; 2009 Sep; 19(5):838-56. PubMed ID: 20183447
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
